Enorama Pharma (Sweden) Insiders
| ERMA Stock | SEK 3.77 0.09 2.33% |
Breaking down Enorama Pharma's management performance can provide insight into the firm performance.
| Mats Rnngard Insider CEO Member |
Enorama |
Enorama Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.5277) % which means that it has lost $0.5277 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (32.8791) %, meaning that it generated substantial loss on money invested by shareholders. Enorama Pharma's management efficiency ratios could be used to measure how well Enorama Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Enorama Pharma Workforce Comparison
Enorama Pharma AB is one of the top stocks in number of employees category among its peers. The total workforce of Drug Manufacturers - Specialty & Generic industry is currently estimated at about 1,133. Enorama Pharma maintains roughly 10.0 in number of employees contributing less than 1% to equities under Drug Manufacturers - Specialty & Generic industry.
Enorama Pharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Enorama Pharma AB Price Series Summation is a cross summation of Enorama Pharma price series and its benchmark/peer.
Enorama Pharma Stakeholder
| Mats Rnngard | CEO Member | Profile |
About Enorama Pharma Management Performance
The success or failure of an entity such as Enorama Pharma AB often depends on how effective the management is. Enorama Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enorama management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enorama management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Enorama Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enorama Pharma AB. Check Enorama Pharma's Beneish M Score to see the likelihood of Enorama Pharma's management manipulating its earnings.
Enorama Pharma Workforce Analysis
Traditionally, organizations such as Enorama Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enorama Pharma within its industry.Enorama Pharma Manpower Efficiency
Return on Enorama Pharma Manpower
| Revenue Per Employee | 1.1M | |
| Net Loss Per Employee | 2.8M |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.